nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

07.12.2018 | Image of the Month

Monitoring response of advanced Merkel cell carcinoma to Avelumab with ¹⁸F-FDG PET/CT

verfasst von: Cecilia Vellani, Daniela D’Ambrosio, Luca Licata, Ilaria Vacchieri, Antonio Bernardo, Giuseppe Trifirò

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Excerpt

Merkel cell carcinoma is a rare, aggressive skin cancer with few effective treatments and with poor prognosis in patients with advanced disease. …

Kaufman H, Russel J, Hamid O, Bhatia S, Terheyden P, D’Angelo S, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.CrossRefPubMedPubMedCentral

Bharmal M, Marrel A, Hennessy M, Fofana F, Lambert J, Arnould B. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights. J Comp Eff Res. 2018. https://doi.org/10.2217/cer-2018-0048.

Esgghi N, Lundeen TF, MacKinnon L, Avery R, Kuo PH. 18F-FDG PET/CT for monitoring response of Merkel cell carcinoma to the novel programmed cell death ligand 1 inhibitor Avelumab. Clin Nucl Med. 2018;43:e142–4.

Titel: Monitoring response of advanced Merkel cell carcinoma to Avelumab with 18F-FDG PET/CT
verfasst von: Cecilia Vellani
Daniela D’Ambrosio
Luca Licata
Ilaria Vacchieri
Antonio Bernardo
Giuseppe Trifirò
Publikationsdatum: 07.12.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4230-x

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

Open Access
Original Article

18F-FDG PET/CT in multiple myeloma: critical insights and future directions

Letter to the Editor

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Original Article

Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans

Short Communication

Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis

Original Article

Deauville score: the Phoenix rising from ashes

Editorial

Springer Medizin

Monitoring response of advanced Merkel cell carcinoma to Avelumab with ¹⁸F-FDG PET/CT

Excerpt

Weitere Artikel der Ausgabe 5/2019

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

18F-FDG PET/CT in multiple myeloma: critical insights and future directions

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans

Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis

Deauville score: the Phoenix rising from ashes

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

18F-FDG PET/CT in multiple myeloma: critical insights and future directions

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans

Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis

Deauville score: the Phoenix rising from ashes